spacer
home > ict > autumn 2018 > clinical complexities
PUBLICATIONS
International Clinical Trials

Clinical Complexities

ICT: What are the main challenges faced by pharmaceutical companies when moving a candidate compound from the discovery lab through to first-inhuman (FIH) studies?

Torkel Gren and Anders Millerhovf: Moving a promising compound from the laboratory to the clinic is a complex, multistage challenge. You need to coordinate API production with formulation development and trial planning. The only way to do this effectively is for the teams involved in each of these processes to communicate properly.

Specific challenges include the limited quantities of API that are available, the need to develop formulations appropriate for FIH studies and for later-stage trials in parallel, and the ability to adapt to clinical protocol revisions. Effective communication between supply, formulation, and trial teams is vital, and achieving this can be a challenge, particularly if several different contractors are involved.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Torkel Gren is Senior Director, and Science and Technology Officer at Recipharm. He holds degrees in pharmacy and business administration, as well a PhD in pharmaceutics from Uppsala University, Sweden. Torkel has worked in the pharma industry since 1988 and has held a number of scientist and manager positions in Europe and the US. He was lead formulator and co-inventor of Detrol OD/Detrusitol SR. Torkel is Vice Chairman of the board of the Swedish Pharmaceutical Society.

Anders Millerhovf is Chief Executive Officer at Clinical Trial Consultants. He holds a degree in medical biology from Linkoping University, Sweden. Anders has worked in the life sciences industry since 2002 and has focussed on Phase 0 to Phase 2a projects in various project management and director positions. He has been a partner at Clinical Trial Consultants since 2012.
spacer
Torkel Gren
spacer
spacer
spacer
Anders Millerhovf
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Protein Therapeutics

Reading Scientific Services Ltd (RSSL)


More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement